罗氏公司血管内皮生长因子抗体技术专利分析  

Analysis of VEGF antibody technology patents of roche

作　　者：张弛[1] 张颖慧[2] 

机构地区：[1]国家知识产权局专利局医药生物发明审查部,北京100088 [2]国家知识产权局专利局审查业务管理部,北京100088

出　　处：《科技导报》2016年第11期48-52,共5页Science & Technology Review

摘　　要：检索了罗氏公司血管内皮生长因子(vascular endothelial growth factor,VEGF)抗体相关专利申请情况,分析了贝伐珠单抗和兰尼单抗的技术研发路线、罗氏公司VEGF抗体相关在华专利布局情况,对其未来技术研发趋势和方向进行了预测。This paper analyzes the technical development route of bevacizumab and ranibizumab based on the vascular endothelial growth factor（VEGF） antibody related patent applications of Roche. The layout in China of the VEGF related patents of Roche is also analyzed. Based on the above analyses, the future trends and directions of the technical research and development of VEGF antibody technology are predicted.

关 键 词：罗氏公司 VEGF抗体 专利分析 

分 类 号：R979.1[医药卫生—药品] G306[医药卫生—药学]